-transparent.png){kind=logo}
Cicletanine, a drug which affects membrane ion transport, induces a marked increase of the liberation of PGI2 as demonstrated by the increase of the stable metabolites in the plasma following intravenous administration of arachidonic acid. Furthermore, the inhibiting effect of tranylcypromine on prostacyclin synthetase is completely removed by this pharmacon. These observations are suggestive that this drug presents a scope for treatment of thrombotic disorders as well as hypertension.
Related Publications
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
January 1979,
Acta obstetricia et gynecologica Scandinavica. Supplement,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
June 2021,
Pharmaceutics,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
October 1970,
Midwife and health visitor,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
April 1995,
Drug safety,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
January 1983,
Endocrine reviews,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
January 1971,
Molecular pharmacology,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
May 1983,
The American journal of physiology,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
January 1984,
Biochemical and biophysical research communications,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
March 1982,
Pharmacological research communications,
C Deby, and
R H Bourgain, and
R Andries, and
P Braquet
January 2012,
Frontiers in physiology,
